The dashed line represents the average CR participation rate (31.3%) of the analytic cohort (N = 83 687). AP indicates angina pectoris; CABG, coronary artery bypass grafting; NSTEMI, non–ST-segment elevation myocardial infarction; PCI, percutaneous coronary intervention; and STEMI, ST-segment elevation myocardial infarction.
Cardiac rehabilitation (CR) participation was associated with statistically significantly better event-free survival compared with nonparticipation (log-rank test comparing curves, P < .001 for overall survival).
Data are presented on a logarithmic scale. A 32% lower risk of all-cause mortality was found for the total cohort, and adjusted HRs between 0.38 (95% CI, 0.27-0.53) and 0.89 (95% CI, 0.55-1.46) were observed across subgroups. Participation in CR is favored for all subgroups because risk estimates were all less than 1. However, a nonstatistically significant risk reduction was observed for patients with dementia likely because of the small sample size, contributing to a wide 95% CI. AP indicates angina pectoris; CABG, coronary artery bypass grafting; NSTEMI, non–ST-segment elevation myocardial infarction; PCI, percutaneous coronary intervention; and STEMI, non–ST-segment elevation myocardial infarction.
eTable 1. Yearly Inclusion Rate of Patients Eligible for CR Participation Among the VGZ Cohort
eTable 2. Crude and Multivariable Adjusted Hazard Ratios for All-Cause Mortality Among CR Participants
eTable 3. Sensitivity Analyses for Different Thresholds of Minimal Follow-up Time
eFigure 1. The VGZ Cohort Is a Valid Representation of the Dutch Population
eFigure 2. Flowchart of Patient Enrollment From the VGZ Health Insurance Database
Customize your JAMA Network experience by selecting one or more topics from the list below.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Eijsvogels TMH, Maessen MFH, Bakker EA, et al. Association of Cardiac Rehabilitation With All-Cause Mortality Among Patients With Cardiovascular Disease in the Netherlands. JAMA Netw Open. 2020;3(7):e2011686. doi:10.1001/jamanetworkopen.2020.11686
What is the patient-specific, disease-specific, and comorbidity-specific association of cardiac rehabilitation participation with all-cause mortality?
In this cohort study, 31% of 83 687 eligible patients with cardiovascular disease participated in a multidisciplinary outpatient cardiac rehabilitation program. Cardiac rehabilitation participation was associated with a 32% lower risk of all-cause mortality compared with nonparticipation, which was independent of patient-related and comorbidity-related characteristics.
Cardiac rehabilitation participation is associated with a lower mortality risk compared with nonparticipation; however, cardiac rehabilitation remains underused, especially in older adults with chronic diseases or multimorbidity.
Cardiac rehabilitation (CR) is an effective strategy to improve clinical outcomes, but it remains underused in some subgroups of patients with cardiovascular disease (CVD).
To investigate the implications of sex, age, socioeconomic status, CVD diagnosis, cardiothoracic surgery, and comorbidity for the association between CR participation and all-cause mortality.
Design, Setting, and Participants
Observational cohort study with patient enrollment between July 1, 2012, and December 31, 2017, and a follow-up to March 19, 2020. The dates of analysis were March to May 2020. This study was performed among Dutch patients with CVD with a multidisciplinary outpatient CR program indication and who were insured at Coöperatie Volksgezondheidszorg, one of the largest health insurance companies in the Netherlands. Among 4.1 million beneficiaries, patients with CVD with an acute coronary event (myocardial infarction or unstable angina pectoris), stable angina pectoris, chronic heart failure, or cardiothoracic surgery (coronary artery bypass grafting, valve replacement, or percutaneous coronary intervention) were identified by inpatient diagnosis codes and included in the study.
Main Outcomes and Measures
Cox proportional hazards models were used to evaluate the association between CR participation and all-cause mortality. Stabilized inverse propensity score weighting was used to account for patient and disease characteristics associated with CR participation.
Among 83 687 eligible patients with CVD (mean [SD] age, 67  years; 60.4% [n = 50 512] men), only 31.3% (n = 26 171) participated in CR, with large variation across different subgroups (range, 5.1%-73.0%). During a mean (SD) of 4.7 (1.8) years of follow-up, 1966 CR participants (7.5%) and 13 443 CR nonparticipants (23.4%) died. After multivariable adjustment, CR participation was associated with a 32% lower risk of all-cause mortality (adjusted hazard ratio, 0.68; 95% CI, 0.65-0.71) compared with nonparticipation. Sex, age, socioeconomic status, and comorbidity did not alter risk reduction after CR participation, but a statistically significant interaction association was found across categories of CVD diagnosis and cardiothoracic surgery. Larger reductions in risk estimates for all-cause mortality were found after CR participation for STEMI (adjusted HR, 0.59; 95% CI, 0.52-0.68 vs 0.72; 95% CI, 0.65-0.79; P < .001), NSTEMI (adjusted HR, 0.64; 95% CI, 0.58-0.70 vs 0.72; 95% CI, 0.65-0.79; P < .001), and stable AP (adjusted HR, 0.69; 95% CI, 0.63-0.76 vs 0.72; 95% CI, 0.65-0.79; P < .001) compared with patients with chronic heart failure, whereas unstable AP had a smaller risk reduction (adjusted HR, 0.75; 95% CI, 0.67-0.85 vs 0.72; 95% CI, 0.65-0.79; P < .001).
Conclusions and Relevance
In this cohort study, CR participation was associated with a 32% risk reduction in all-cause mortality, and this benefit was independent of sex, age, socioeconomic status, and comorbidity. These findings reinforce the importance of CR participation in secondary prevention and highlight the possibility that CR should be prescribed more widely to vulnerable patients with CVD, such as older adults with chronic diseases or multimorbidity.
Cardiac rehabilitation (CR) is a key component of secondary prevention strategies for patients with cardiovascular disease (CVD).1 Risk reduction for all-cause mortality, CVD mortality, unplanned hospitalization, and reinfarction has been reported in CR participants vs nonparticipants in multiple meta-analyses.2-6 Therefore, the American Heart Association, American College of Cardiology, and European Society of Cardiology have included CR referral as a Class IA recommendation for stable patients after an acute coronary syndrome or heart failure diagnosis.7-10 Despite these strong recommendations, participation rates of patients with CVD among hospital-based CR programs remain low, varying between 10% and 35% of eligible patients.11,12 Demographic and clinical factors, such as female sex, advanced age, socioeconomic status (SES), recent cardiothoracic surgery, and existing comorbidity, are known to reduce CR referral and participation,13,14 but evidence to refute these referral biases is scarce.
The present study aimed to investigate the implications of sex, age, SES, CVD diagnosis, cardiothoracic surgery, and comorbidity for the association between participation in a multidisciplinary outpatient CR program and all-cause mortality risk reduction. The study analyzed health insurance claims data from a nationwide cohort of 4.1 million individuals in the Netherlands. We hypothesized that participation in CR would be associated with a lower mortality risk for patients with CVD compared with nonparticipation, and we expected the risk reduction would vary across subgroups with different risk profiles.
In the Netherlands, it is mandatory to have health insurance. For the present study, health insurance claims data were used from Dutch patients with CVD with a multidisciplinary outpatient CR program indication and who were insured at Coöperatie Volksgezondheidszorg (VGZ), one of the largest health insurance companies in the Netherlands. The VGZ cohort consists of 4.1 million beneficiaries, representing 24% of the Dutch population,15 with nationwide coverage and a representative sample of individuals from all age categories, SES, and both rural and urban areas (eFigure 1 in the Supplement). Individuals eligible for the present study were patients with a new diagnosis of CVD with an indication for CR according to Dutch guidelines,16 including an acute coronary event (myocardial infarction [MI] or unstable angina pectoris [AP]), stable AP, chronic heart failure, or cardiothoracic surgery (coronary artery bypass grafting [CABG], valve replacement, or percutaneous coronary intervention [PCI]). Reimbursement for outpatient CR is provided on the condition that the patient is referred by a cardiologist. Health insurance claims data were used to assess the type and date of diagnosis, and patients were enrolled between July 1, 2012, and December 31, 2017, with follow-up to March 19, 2020. The dates of analysis were March to May 2020. This study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline. The Radboud University Medical Center Institutional Review Board deemed that this observational cohort study was exempt from informed consent because it involved retrospective analysis of an anonymized data set.
The Dutch Society of Cardiology released a multidisciplinary CR guideline,16 which is consistent with international recommendations.17,18 Group-based outpatient CR programs consist of the following 4 modules: (1) supervised exercise training, (2) mental health and stress relief, (3) social health, and (4) cardiovascular risk management. The multidisciplinary CR program typically lasts 6 to 12 weeks; on average, 85% of the patients receive exercise training, 39% receive relaxation therapy, 17% receive lifestyle modification therapy, and 75% receive education.19 Hence, the content of the contemporary Dutch CR program is largely comparable to that of CR programs in other countries. Accessibility to CR in the Netherlands is excellent because most CR facilities are located near the residence of patients (<30 km).
A total of 101 940 patients met the initial selection criteria. Consistent with previous observational studies,20,21 patients were classified as having received CR if a claim was filed for at least one of the group-based outpatient treatments. Excluded from further analysis were patients who (1) were insured less than 365 days before or less than 180 days after their diagnosis of CVD, (2) began CR more than 90 days after their diagnosis, or (3) died within 180 days after their diagnosis. Patients with multiple CVD-related insurance claims within 30 days after the initial diagnosis were reclassified according to the most severe diagnosis using the following rankings for CVD diagnosis and cardiothoracic surgery.20 For CVD diagnosis, the ranking was (1) ST-segment elevation MI (STEMI), (2) non-STEMI (NSTEMI), (3) unstable AP,(4) stable AP, and (5) chronic heart failure. For cardiothoracic surgery, the ranking was (1) CABG, (2) valve replacement, (3) acute PCI, and (4) elective PCI. Accordingly, 83 687 eligible patients with CVD were available for analysis (eFigure 2 in the Supplement).
Survival status of study participants was obtained from the Dutch Population Register, and the date of death was extracted if applicable. All-cause mortality was the primary outcome, and survival time in days was calculated from the date of the initial diagnosis of CVD. The maximum follow-up in the cohort was 7.7 years (92 months). Patients were censored if they switched to another health insurance company or if they were still alive during the last survival check.
Sex and age were extracted from the VGZ health insurance database. Income and SES were obtained from the national statistical office (Statistics Netherlands) using postal code information for the patient’s residence. Socioeconomic status was classified using the SES score from Statistics Netherlands as low (bottom 40%), moderate (middle 30%), or high (upper 30%) (eFigure 1C in the Supplement).
Comorbidity was identified using diagnosis codes from the Dutch Business Intelligence Center for Healthcare (Vektis). Insurance claims data for pharmaceutical agents were used to evaluate the association of diabetes, cancer, gout, Parkinson disease, respiratory diseases, thyroid diseases, and dementia as binary variables with CR outcomes.22 We evaluated the consequences of multimorbidity using the Charlson Comorbidity Index (CCI). As a continuous variable, the CCI was calculated as the sum of comorbid conditions23 as follows. One point was given for MI, congestive heart failure, peripheral vascular disease, cerebrovascular disease, dementia, chronic pulmonary disease, ulcer disease, mild liver disease, and diabetes. Two points were given for diabetes with end-organ damage, any tumor, leukemia, and lymphoma. Three points were given for moderate to severe liver disease. Six points were given for metastatic solid tumors and AIDS. We compared the association of CR with all-cause mortality across patients with CCI scores of 1 or less, 2, 3, 4, and 5 or greater.
Baseline characteristics were summarized as mean (SD) or median (interquartile range) for continuous variables and as number (percentage) for categorical variables. Differences in individual and disease characteristics between CR participants and nonparticipants were assessed using t test for continuous variables and χ2 test for categorical variables. Kaplan-Meier curves and a log-rank test were used to assess the difference in all-cause mortality between CR participants and nonparticipants.
Information about patient characteristics, income, SES, distance to CR facility, disease characteristics, comorbidity, pharmaceutical agents in the year of diagnosis of CVD, and health care expenses was used to calculate the inverse propensity score. The crude hazard ratio (HR) (with 95% CI) was calculated by univariable Cox proportional hazards models. Subsequently, we corrected for sex, age, category of CVD diagnosis, cardiothoracic surgery, Charlson Comorbidity Index, and cardiac medication. Stabilized inverse propensity score weighting was applied to the fully adjusted multivariable Cox proportional hazards models to account for differences between CR participants and nonparticipants.24-26 We evaluated the robustness of the main outcomes via sensitivity analyses. For this purpose, the period between the initial event date and the minimum follow-up period was changed from 180 days to 1 to 6 years.
The presence of effect modification was tested for using an interaction term to assess the implications of sex (reference group, men), age (reference group, <50 years), SES (reference group, low SES), CVD diagnosis (reference group, chronic heart failure), cardiothoracic surgery (reference group, elective PCI), and comorbidity (reference group, CCI≤1) for the association between CR participation and all-cause mortality risk. Two-sided P < .05 was considered statistically significant. All statistical analyses were performed in SAS, version 9.4 (SAS Institute Inc).
In this cohort of 83 687 patients with CVD (mean [SD] age, 67  years; 60.4% [n = 50 512] men), only 31.3% (n = 26 171) participated in CR at 89 CR facilities in the Netherlands. The CR participation rate increased across calendar years from 25.7% in 2012 to 38.6% in 2017 (eTable 1 in the Supplement). Distance to the CR facility was greater for CR participants than for nonparticipants (mean [SD], 15.4 [19.3] vs 14.7 [20.2] km; P < .001). Compared with nonparticipants, CR participants were younger, included more male patients, had a lower CCI score, and had a higher income (Table 1). Cardiac medication use was lower in the year before CVD diagnosis among CR participants compared with nonparticipants, but this association largely reversed in the year after CVD diagnosis. Cardiac rehabilitation participation rates were higher among men (37.2%), patients younger than 75 years (33.5% to 39.8%), those with a diagnosis of STEMI (66.6%) or NSTEMI (49.2%), those with a CCI score of 3 or less (32.0% to 41.7%), and those undergoing CABG (73.0%), valve replacement (54.8%), or acute (66.0%) or elective (41.8%) PCI. In contrast, CR was underused in women (22.2%), patients 75 years or older (6.7% to 21.5%), those with comorbidity (12.7% to 26.5%), and those having a CVD diagnosis of unstable (25.9%) or stable (15.9%) AP or chronic heart failure (5.1%) (Figure 1).
During a mean (SD) of 4.7 (1.8) years of follow-up (56  months), 1966 CR participants (7.5%) and 13 443 nonparticipants (23.4%) died (P < .001) (Table 2). Kaplan-Meier analysis revealed that CR participation was associated with better event-free survival (Figure 2). Cox proportional hazards models showed a 68% lower risk of all-cause mortality (crude HR, 0.32; 95% CI, 0.30-0.33) in CR participants compared with nonparticipants (Table 2). Mortality risk remained lower in CR participants after stepwise correction for confounders (adjusted HR, 0.68; 95% CI, 0.65-0.71) (eTable 2 in the Supplement). After multivariable adjustment, CR participation was associated with a 32% lower risk of all-cause mortality (adjusted HR, 0.68; 95% CI, 0.65-0.71) compared with nonparticipation. Mortality rates during follow-up were variable across subgroups (Table 2), ranging from 1.3% to 63.9%. Cardiac rehabilitation participation was associated with improved event-free survival and a statistically significantly lower risk of all-cause mortality among all subgroups, except for patients with dementia (Figure 3). Sex, age, SES, and comorbidity did not alter risk reduction after CR participation, with no effect modification observed. However, a statistically significant interaction association was found across categories of CVD diagnosis and cardiothoracic surgery. Larger reductions in risk estimates for all-cause mortality were found after CR participation for STEMI (adjusted HR, 0.59; 95% CI, 0.52-0.68 vs 0.72; 95% CI, 0.65-0.79; P < .001), NSTEMI (adjusted HR, 0.64; 95% CI, 0.58-0.70 vs 0.72; 95% CI, 0.65-0.79; P < .001), and stable AP (adjusted HR, 0.69; 95% CI, 0.63-0.76 vs 0.72; 95% CI, 0.65-0.79; P < .001) compared with patients with chronic heart failure, whereas unstable AP had a smaller risk reduction (adjusted HR, 0.75; 95% CI, 0.67-0.85 vs 0.72; 95% CI, 0.65-0.79; P < .001). Effect modification was also present for cardiothoracic surgery, with acute PCI having a larger reduction in the risk estimate for all-cause mortality after CR participation (adjusted HR, 0.64; 95% CI, 0.57-0.72 vs 0.82; 95% CI, 0.74-0.91; P < .001) compared with elective PCI, whereas no difference in risk reduction was found for CABG (adjusted HR, 0.75; 95% CI, 0.63-0.90 vs 0.82; 95% CI, 0.74-0.91; P = .53) or valve replacement (adjusted HR, 0.76; 95% CI, 0.62-0.93 vs 0.82; 95% CI, 0.74-0.91; P = .53).
To evaluate the robustness of the main outcomes, the adjusted HRs of CR participation on all-cause mortality were recalculated. For this purpose, mortality risk reduction for different durations during follow-up was calculated. These sensitivity analyses showed risk reduction for all-cause mortality similar to the initial findings (adjusted HR, 0.68-0.86) (eTable 3 in the Supplement).
Cardiac rehabilitation programs aim to improve prognosis and quality of life via a multifaceted intervention. The present study demonstrated that CR participation was associated with a 32% lower risk of all-cause mortality compared with nonparticipation after adjustment for confounding factors. The association between CR participation and all-cause mortality was independent of sex, age, socioeconomic status, and comorbidity, but the magnitude of risk reduction after CR differed across categories of CVD diagnosis and type of cardiothoracic surgery. On average, the CR participation rate was 31.3%, but it increased from 25.7% in 2012 to 38.6% in 2017. Large variation in CR use was observed (range, 5.1%-73.0%) across different subgroups. Findings from this Dutch nationwide observational cohort study underscore the health benefit of CR and emphasize the need to better use CR, such as improving referral and encouragement by clinicians, particularly in vulnerable patients with CVD (eg, older individuals or those with comorbidity or multimorbidity).
The crude risk reduction in all-cause mortality after CR participation was 68%, which was reduced to 32% after adjustment for confounding factors. The quantification of mortality risk reduction in the present study is substantially larger compared with outcomes of previously published meta-analyses (−1% to 13%).2,5,27,28 A potential explanation for the discrepant outcomes may relate to the study design. We used an observational population-based cohort to study the health benefit of CR in a real-world setting, yielding high external validity. This design is in contrast to meta-analyses, which use data from randomized clinical trials (RCTs). Although RCTs may reduce the risk of confounding because of randomization, vulnerable patients (eg, older individuals or those with comorbidity or multimorbidity) are typically excluded. Hence, RCTs have high internal validity but typically have lower external validity.29 The health benefit of CR may be larger in patients who are underrepresented in or excluded from RCTs. Alternatively, the content of the CR program may alter the outcomes.17 Our patients were enrolled in a multidisciplinary program, including supervised exercise training, mental health and stress relief, social health, and cardiovascular risk management,16 whereas most RCTs compared exercise-based CR with a control condition.5 Hence, mortality risk reduction may have been larger in our cohort because of the multifaceted treatment that patients received.30 Indeed, our findings align with other large observational population studies20,31,32 reporting a 33% to 35% risk reduction in CR participants. Independent of the risk reduction of the present study vs data from RCTs, these joint outcomes further reinforce the Class IA recommendation for CR participation in current and future clinical guidelines of professional associations.7-10
A unique aspect of the present study is the assessment of mortality risk across different subgroups of patients eligible for CR. Better survival was found for all subgroups participating in CR. The magnitude of risk reduction after CR differed statistically significantly across categories of CVD diagnosis and type of cardiothoracic surgery, but risk estimates and their 95% CIs were less than 1 for every subgroup (Figure 3), indicating that CR participation provides a better outcome than nonparticipation. This finding is notable because the level of evidence of CR health benefits is weak for some subgroups. Few studies on CR report sex-specific outcomes,33 but risk reduction after CR differs between men and women.20 Although CR use is lower in women than in men, we observed a similar mortality risk reduction with CR participation in men (32.1%) and women (31.3%) (Figure 3), suggesting that both sexes benefit equally from CR.
Older patients are often underrepresented in CR programs, despite their higher disease prevalence.34 Hence, recommendations for treatment of older patients (≥75 years) are needed that are typical of those individuals encountered in routine clinical practice.35 Age did not alter the association between CR participation and better mortality outcomes. In fact, CR was associated with large reductions in all-cause mortality in patients aged 75 to 84 years (27.8%) and 85 years or older (32.0%) (Figure 3). These findings suggest that CR improves survival even in older age groups, which have mortality rates of up to 63.9%.
The implications of CR for mortality in patients with stable AP remain unclear. In a recent systematic review and meta-analysis28 (including 7 studies and 581 patients), risk estimates could not be calculated because of insufficient power. Among 24 549 patients with stable AP in our study, CR participation was associated with a 31% mortality risk reduction (adjusted HR, 0.69; 95% CI, 0.63-0.77) (Figure 3). Similarly, among 13 813 patients with unstable AP, CR participation was associated with a 25% mortality risk reduction (adjusted HR, 0.75; 95% CI, 0.67-0.85). Our observations underscore the mortality benefit of CR for patients with stable AP and patients with unstable AP.
Multiple comorbid conditions are increasingly prevalent among patients with CVD.36 Patients with multimorbidity have a worse prognosis37 and a lower CR participation rate,38 and current clinical practice is mainly targeted toward care of patients with a single disease. We found that CR participants with diabetes, cancer, gout, Parkinson disease, respiratory diseases, and thyroid diseases had better survival rates compared with nonparticipants. Patients with CVD with dementia did not demonstrate a statistically significant risk reduction after CR, but the risk estimate indicated a 10.8% reduction in all-cause mortality (adjusted HR, 0.89; 95% CI, 0.55-1.46) (Figure 3). The lack of statistical significance is likely because of the small sample size (n = 393), which contributed to a wide 95% CI (−45% to 46%). Cardiac rehabilitation participation among patients with CVD with the highest CCI scores was associated with notable risk reduction (≥30%). These findings emphasize that CR has substantial health value for patients with CVD with comorbidity and should lead clinicians to encourage their patients to participate in CR.
Findings from the present study not only reinforce the health benefit of CR but also demonstrate the underuse of this powerful intervention. Only 31.3% of eligible Dutch patients participated in CR, which is high compared with US data11,12 but is similar to values reported in European studies.39,40 However, more notable is the increase in CR use from 25.7% in 2012 to 38.6% in 2017. Future studies are warranted to elucidate the reasons for this substantial improvement as well as to understand temporal changes in predictors of participation. Outcomes from such analyses can be used to develop strategies to further increase CR use across the globe.
Large variability in CR participation rates across different subgroups was also observed. Participation rates were high for medical conditions with clear guidelines and strong recommendations, such as STEMI9 (66.6%), CABG7 (73.0%), valve replacement7 (54.8%), and acute (66.0%) or elective (41.8%) PCI.41 Participation rates were low in subgroups with chronic conditions, such as older patients and those with stable AP, chronic heart failure, comorbidities (ie, diabetes, cancer, gout, etc), and multimorbidity (CCI≥4) (Figure 1). The lower participation rates likely relate to the frailty of these patients, a lack of physician referral, or to practical barriers, such as a lack of transportation.42 Alternative strategies to deliver CR, such as home-based CR,43,44 telerehabilitation,45 or eHealth interventions,46 may enable patients with CVD to profit from CR.
This study has some limitations. The main limitation is its observational design. Analyses based on CR components were not possible to perform because of a change in the medical claims registry system during the study period and an insufficient level of detail regarding the number of sessions and the combination of components. The use of health insurance claims data did not allow us to control for all potential confounding factors, such as cardiovascular risk factors, disease severity, lifestyle (eg, physical activity, smoking, and diet), and patient motivation. Nevertheless, we were able to extract data regarding patient characteristics, CVD diagnosis, type of cardiothoracic surgery, hospital stay, pharmaceutical agent use, comorbidity, and health care costs to correct for differences between CR participants and nonparticipants. Stabilized inverse propensity score weighting was used to create a pseudopopulation and subsequently adjust for the covariates in the Cox proportional hazards models to minimize potential group differences. Matched-pairs analysis (n = 32 780) confirmed the findings of our primary analysis (data not shown). Race was not available, but most of the Dutch population is of white race/ethnicity (approximately 87.7%).47 Residual confounding may have occurred because unmeasured variables could explain some of the observed mortality differences between CR participants and nonparticipants. However, results from the present study demonstrated a consistent mortality risk reduction among all subgroups of CR participants, and the health benefit of CR was further reinforced in the sensitivity analyses. Finally, the inclusion of a large and heterogeneous patient population in combination with the high accuracy of health insurance data48 supports the value of the present study beyond previously published RCTs and meta-analyses.
After multivariable adjustment, participation in a multidisciplinary CR program was associated with 32% lower risk of all-cause mortality (adjusted HR, 0.68; 95% CI, 0.65-0.71) compared with nonparticipation during a mean (SD) of 4.7 (1.8) years of follow-up. The survival benefit associated with CR participation was observed in virtually all subgroups of patients with CVD (except for patients with dementia), including risk estimates specific to sex, age, SES, CVD diagnosis, cardiothoracic surgery, and comorbidity. Findings from the present study further reinforce current recommendations of the American Heart Association, American College of Cardiology, and European Society of Cardiology and suggest that CR should be prescribed more widely to vulnerable patients with CVD, such as older adults with chronic diseases or multimorbidity. Cardiac rehabilitation participation rates remain low in these at-risk subgroups, whereas the benefits of cardiac rehabilitation are similar to those of low-risk subgroups.
Accepted for Publication: May 17, 2020.
Published: July 27, 2020. doi:10.1001/jamanetworkopen.2020.11686
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2020 Eijsvogels TMH et al. JAMA Network Open.
Corresponding Author: Thijs M. H. Eijsvogels, PhD, Department of Physiology, Radboud Institute for Health Sciences, Radboud University Medical Centre, PO Box 9101, 6500 HB Nijmegen, the Netherlands (email@example.com).
Author Contributions: Dr Maessen had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs Eijsvogels and Maessen contributed equally to this work and are considered co–first authors.
Concept and design: Maessen, Bakker, Meindersma, van Gorp, Pijnenburg, Hopman.
Acquisition, analysis, or interpretation of data: Eijsvogels, Maessen, Bakker, Meindersma, van Gorp, Thompson, Hopman.
Drafting of the manuscript: Eijsvogels, van Gorp, Thompson.
Critical revision of the manuscript for important intellectual content: Maessen, Bakker, Meindersma, Pijnenburg, Thompson, Hopman.
Statistical analysis: Eijsvogels, Maessen.
Obtained funding: Hopman.
Administrative, technical, or material support: van Gorp, Hopman.
Supervision: Eijsvogels, Pijnenburg, Hopman.
Conflict of Interest Disclosures: Dr Maessen reported receiving personal fees from Coöperatie Volksgezondheidszorg (VGZ) and grants from Interreg. Mr van Gorp and Ms Pijnenburg reported receiving personal fees from VGZ. Dr Thompson reported receiving research grants from Amarin, Regeneron, and Sanofi; serving as a consultant for Regeneron and Sanofi; receiving speaker honoraria from Amgen, Amarin, and Boehringer Ingelheim; and owning stock in Abbott, AbbVie, CVS, Sarepta, and MyoKardia. No other disclosures were reported.
Funding/Support: This project was supported by a European Territorial Cooperation (Interreg) grant (Zorg Verbindt 203072). Dr Eijsvogels is supported by the Netherlands Heart Foundation (Senior E-Dekker grant 2017T051).
Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Create a personal account or sign in to: